JOURNAL 595


Records of Natural Products
VOLUME & ISSUE
Year: 2012 Issue: 2 April-June
PAGES
p.110 - 120
STATISTICS
Viewed 1946 times.
AUTHORS
    Chongming Wu , Jingyao Shen, Pingping He, Yan Chen, Liang Li, Liang Zhang, Ye Li, Yujuan Fu, Weiwei Meng, Yulin Deng
PDF OF ARTICLE

GRAPHICAL ABSTRACT


ABSTRACT


I The dried rhizome of Belamcanda chinensis is an important Chinese traditional medicine used for the treatment of inflammation and many other disorders. Previously, we reported the hypo- and antihyper-glycemic effects of the aqueous leaf extract of B. chinensis (BCL) and identified the isoflavones as its principal active fraction. In the present study, the α-glucosidase inhibitory effect of BCL and its rough isoflavone preparation (BIF) was tested in vitro and in vivo. Thirteen isoflavones were isolated from BCL and their α-glucosidase inhibitory activity was screened in vitro. The results showed that BCL (500 and 1000 mg/kg) and BIF (250 and 500 mg/kg) greatly inhibited the increase in blood glucose level after 5 g/kg starch loading in normal mice. Six out of the thirteen isoflavones (swertisin, 2 ” -O-rhamnosylswertisin, genistein, genistin, mangiferin and daidzin) exhibited strong α-glucosidase inhibitory activity in vitro. HPLC analysis showed that swertisin was the most abundant isoflavone in BCL accounting for 1.24% of BCL, 7.44% of BIF, and 11.24% of the total isoflavone fraction of BCL, respectively. These results demonstrate that BCL possesses significant α-glucosidase inhibitory activity and swertisin may be the principal active component of BCL in α-glucosidase inhibition.

KEYWORDS
  • Belamcanda chinensis
  • diabetes
  • α-glucosidase inhibitor
  • swertisin
  • isoflavones
  • postprandial hyperglycemia.